# Marc P. Bonaca

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/marc-p-bonaca/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,771 |
| Field | Peripheral Artery Disease Management |
| h-index | 70 |
| i10-index | 215 |
| Last Known Institution | The Medical Center of Aurora |
| OpenAlex ID | https://openalex.org/A5090903599 |
| ORCID iD | https://orcid.org/0000-0002-9860-3584 |
| Works | 584 |

## Researcher papers

- [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials](https://scholariq.org/papers/sglt2-inhibitors-for-primary-and-secondary-prevention-of-cardiovascular-and/)
- [Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction](https://scholariq.org/papers/long-term-use-of-ticagrelor-in-patients-with-prior-myocardial-infarction/)
- [Rivaroxaban in Peripheral Artery Disease after Revascularization](https://scholariq.org/papers/rivaroxaban-in-peripheral-artery-disease-after-revascularization/)
- [Vorapaxar in the Secondary Prevention of Atherothrombotic Events](https://scholariq.org/papers/vorapaxar-in-the-secondary-prevention-of-atherothrombotic-events/)
- [Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus](https://scholariq.org/papers/comparison-of-the-effects-of-glucagon-like-peptide-receptor-agonists-and-sodium/)
- [Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus](https://scholariq.org/papers/effect-of-dapagliflozin-on-heart-failure-and-mortality-in-type-2-diabetes/)
- [Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus](https://scholariq.org/papers/effect-of-dapagliflozin-on-atrial-fibrillation-in-patients-with-type-2-diabetes/)
- [Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study](https://scholariq.org/papers/odanacatib-for-the-treatment-of-postmenopausal-osteoporosis-results-of-the-loft/)
- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)

## Researcher topics

- [Peripheral Artery Disease Management](https://scholariq.org/topics/peripheral-artery-disease-management/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Cerebrovascular and Carotid Artery Diseases](https://scholariq.org/topics/cerebrovascular-and-carotid-artery-diseases/)

## Researcher university

- [The Medical Center of Aurora](https://scholariq.org/institutions/the-medical-center-of-aurora/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.